Tuberous Sclerosis, Type II Diabetes Mellitus and the PI3K/AKT/mTOR Signaling Pathways-Case Report and Literature Review

被引:7
|
作者
Jurca, Claudia Maria [1 ,2 ]
Kozma, Kinga [1 ,2 ]
Petchesi, Codruta Diana [1 ,2 ]
Zaha, Dana Carmen [1 ]
Magyar, Ioan [1 ]
Munteanu, Mihai [3 ]
Faur, Lucian [3 ]
Jurca, Aurora [4 ]
Bembea, Dan [5 ]
Severin, Emilia [6 ]
Jurca, Alexandru Daniel [1 ]
机构
[1] Univ Oradea, Fac Med & Pharm, Dept Preclin Disciplines, Oradea 410081, Romania
[2] Cty Emergency Clin Hosp Oradea, Reg Ctr Med Genet Bihor, Oradea 410469, Romania
[3] Univ Oradea, Fac Med & Pharm, Dept Med Disciplines, Oradea 410081, Romania
[4] Univ Oradea, Fac Med & Pharm, Oradea 410081, Romania
[5] Univ Med & Pharm Iuliu Hatieganu, Fac Med, Cluj Napoca 400012, Romania
[6] Univ Med & Pharm Carol Davila, Dept Genet, Bucharest 020021, Romania
关键词
tuberous sclerosis; hamartomas; TSC1; TSC2; epilepsy; type 2 diabetes mellitus; Metformin; MAMMALIAN TARGET; GLUCOSE-UPTAKE; COMPLEX; TSC1; MTOR; CELL; KINASE; EXPRESSION; MANAGEMENT; METFORMIN;
D O I
10.3390/genes14020433
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Tuberous sclerosis complex (TSC) is a rare autosomal dominant neurocutaneous syndrome. It is manifested mainly in cutaneous lesions, epilepsy and the emergence of hamartomas in several tissues and organs. The disease sets in due to mutations in two tumor suppressor genes: TSC1 and TSC2. The authors present the case of a 33-year-old female patient registered with the Bihor County Regional Center of Medical Genetics (RCMG) since 2021 with a TSC diagnosis. She was diagnosed with epilepsy at eight months old. At 18 years old she was diagnosed with tuberous sclerosis and was referred to the neurology department. Since 2013 she has been registered with the department for diabetes and nutritional diseases with a type 2 diabetes mellitus (T2DM) diagnosis. The clinical examination revealed: growth delay, obesity, facial angiofibromas, sebaceous adenomas, depigmented macules, papillomatous tumorlets in the thorax (bilateral) and neck, periungual fibroma in both lower limbs, frequent convulsive seizures; on a biological level, high glycemia and glycated hemoglobin levels. Brain MRI displayed a distinctive TS aspect with five bilateral hamartomatous subependymal nodules associating cortical/subcortical tubers with the frontal, temporal and occipital distribution. Molecular diagnosis showed a pathogenic variant in the TSC1 gene, exon 13, c.1270A>T (p. Arg424*). Current treatment targets diabetes (Metformin, Gliclazide and the GLP-1 analog semaglutide) and epilepsy (Carbamazepine and Clonazepam). This case report presents a rare association between type 2 diabetes mellitus and Tuberous Sclerosis Complex. We suggest that the diabetes medication Metformin may have positive effects on both the progression of the tumor associated with TSC and the seizures specific to TSC and we assume that the association of TSC and T2DM in the presented cases is accidental, as there are no similar cases reported in the literature.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Peruvoside targets apoptosis and autophagy through MAPK Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways in human cancers
    Reddy, Dhanasekhar
    Kumavath, Ranjith
    Tan, Tuan Zea
    Ampasala, Dinakara Rao
    Kumar, Alan Prem
    LIFE SCIENCES, 2020, 241
  • [42] Vertical inhibition of PI3K/Akt/mTOR signaling demonstrates in vitro and in vivo anti-fibrotic activity
    Liang, Minrui
    Lv, Jiaoyan
    Chu, Haiyan
    Wang, Jiucun
    Chen, Xiangjun
    Zhu, Xiaoxia
    Xue, Yu
    Guan, Ming
    Zou, Hejian
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2014, 76 (02) : 104 - 111
  • [43] mTOR Activation by PI3K/Akt and ERK Signaling in Short ELF-EMF Exposed Human Keratinocytes
    Patruno, Antonia
    Pesce, Mirko
    Grilli, Alfredo
    Speranza, Lorenza
    Franceschelli, Sara
    De Lutiis, Maria Anna
    Vianale, Giovina
    Costantini, Erica
    Amerio, Paolo
    Muraro, Raffaella
    Felaco, Mario
    Reale, Marcella
    PLOS ONE, 2015, 10 (10):
  • [44] PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
    Li, HaiXia
    Zeng, JianFang
    Shen, Keng
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2014, 290 (06) : 1067 - 1078
  • [45] Differential impact of PI3K/AKT/mTOR signaling on tumor initiation and progression in animal models of prostate cancer
    Wang, Shuaibin
    Zhang, Chao
    Xu, Zhifang
    Chen, Michael H.
    Yu, Haiyan
    Wang, Lizhong
    Liu, Runhua
    PROSTATE, 2023, 83 (01): : 97 - 108
  • [46] Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling
    Zhao, Yan
    Sun, Hongli
    Feng, Minjuan
    Zhao, Jinyan
    Zhao, Xiaogui
    Wan, Qiuyuan
    Cai, Dongge
    GYNECOLOGICAL ENDOCRINOLOGY, 2018, 34 (05) : 428 - 432
  • [47] Regulation and Importance of the PI3K/Akt/mTOR Signaling Pathway in Hematologic Malignancies
    Kawauchi, Kiyotaka
    Ogasawara, Toshie
    Yasuyama, Masako
    Otsuka, Kuniaki
    Yamada, Osamu
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (09) : 1024 - 1038
  • [48] PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
    Leiphrakpam, Premila D.
    Are, Chandrakanth
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (06)
  • [49] The Cardioprotection of the Insulin-Mediated PI3K/Akt/mTOR Signaling Pathway
    Yao, Hong
    Han, Xiangyang
    Han, Xiuzhen
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2014, 14 (06) : 433 - 442
  • [50] Crosstalk between miRNA and PI3K/AKT/mTOR signaling pathway in cancer
    Akbarzadeh, Maryam
    Mihanfar, Ainaz
    Akbarzadeh, Shabnam
    Yousefi, Bahman
    Majidinia, Maryam
    LIFE SCIENCES, 2021, 285